Orencia Sales Data
| Rank 74 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Orencia U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 74 | $216,942 | 2.68% | 325 | -0.91% |
| Q4 2012 | 74 ( 2) |
$211,272 | 3.89% | 328 | -2.09% |
| Q3 2012 | 76 (6) |
$203,359 | 6.17% | 335 | 1.52% |
| Q2 2012 | 82 (15) |
$191,537 | 11.23% | 330 | 5.10% |
| Q1 2012 | 97 ( ) |
$172,202 |  |
314 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| May 15, 2012 | U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA (abatacept) |
